A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

The 2nd Year Results of C-OPERA, a Study of Anti-TNF-alpha Antibody Certolizumab Pegol, Announced at 2015 ACR/ARHP Annual Meeting
Nov 10, 2015
- The Clinical benefit of initial 1-year CZP treatment was maintained after discontinuation up to another 1-year -